Search Results - "Taylor, Peter C."

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis by Taylor, Peter C

“…Abstract Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus kinase (JAK) enzymes to be approved for the treatment…”
Get full text

Neutralizing monoclonal antibodies for treatment of COVID-19 by Taylor, Peter C., Adams, Andrew C., Hufford, Matthew M., de la Torre, Inmaculada, Winthrop, Kevin, Gottlieb, Robert L.

“…Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under…”
Get full text

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis by Taylor, Peter C, Feldmann, Marc

“…Tumor necrosis factor (TNF) is expressed at high levels in synovial tissue from patients with RA. Through preclinical studies, animal model studies and human…”
Get full text

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database by Taylor, Peter C, Takeuchi, Tsutomu, Burmester, Gerd R, Durez, Patrick, Smolen, Josef S, Deberdt, Walter, Issa, Maher, Terres, Jorge Ross, Bello, Natalia, Winthrop, Kevin L

“…To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid…”
Get more information

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases by Taylor, Peter C

“…Tumor necrosis factor-alpha (TNF) has been unequivocally validated as a therapeutic target in a number of immune-mediated inflammatory disorders (IMIDs). There…”
Get full text

The Jak/STAT pathway: A focus on pain in rheumatoid arthritis by Simon, Lee S., Taylor, Peter C., Choy, Ernest H., Sebba, Anthony, Quebe, Amanda, Knopp, Kelly L., Porreca, Frank

“…Pain is a manifestation of rheumatoid arthritis (RA) that is mediated by inflammatory and non-inflammatory mechanisms and negatively affects quality of life…”
Get full text

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? by Baumgart, Daniel C, Misery, Laurent, Naeyaert, Sue, Taylor, Peter C

“…Biological therapies are an effective treatment for a range of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriasis, and…”
Get full text

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis by Taylor, Peter C, Keystone, Edward C, van der Heijde, Désirée, Weinblatt, Michael E, del Carmen Morales, Liliana, Reyes Gonzaga, Jaime, Yakushin, Sergey, Ishii, Taeko, Emoto, Kahaku, Beattie, Scott, Arora, Vipin, Gaich, Carol, Rooney, Terence, Schlichting, Douglas, Macias, William L, de Bono, Stephanie, Tanaka, Yoshiya

“…In a phase 3 randomized trial of 1307 patients with rheumatoid arthritis receiving background methotrexate, the oral JAK1 and JAK2 inhibitor baricitinib showed…”
Get full text

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations by McInnes, Iain B, Byers, Nicole L, Higgs, Richard E, Lee, Jonathan, Macias, William L, Na, Songqing, Ortmann, Robert A, Rocha, Guilherme, Rooney, Terence P, Wehrman, Thomas, Zhang, Xin, Zuckerman, Steven H, Taylor, Peter C

“…The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the…”
Get full text

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis by Weisel, Kathleen, Berger, Scott, Thorn, Katie, Taylor, Peter C, Peterfy, Charles, Siddall, Hilary, Tompson, Debra, Wang, Susanne, Quattrocchi, Emilia, Burriss, Susan W, Walter, Jochen, Tak, Paul Peter

“…Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter,…”
Get full text

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial by Taylor, Peter C, Saurigny, Didier, Vencovsky, Jiri, Takeuchi, Tsutomu, Nakamura, Tadashi, Matsievskaia, Galina, Hunt, Barbara, Wagner, Thomas, Souberbielle, Bernard

“…Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was…”
Get full text

Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC) by Lliso-Ribera, Gloria, Humby, Frances, Lewis, Myles, Nerviani, Alessandra, Mauro, Daniele, Rivellese, Felice, Kelly, Stephen, Hands, Rebecca, Bene, Fabiola, Ramamoorthi, Nandhini, Hackney, Jason A, Cauli, Alberto, Choy, Ernest H, Filer, Andrew, Taylor, Peter C, McInnes, Iain, Townsend, Michael J, Pitzalis, Costantino

“…To establish whether synovial pathobiology improves current clinical classification and prognostic algorithms in early inflammatory arthritis and identify…”
Get more information

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases by Taylor, Peter C, Choy, Ernest, Baraliakos, Xenofon, Szekanecz, Zoltan, Xavier, Ricardo M, Isaacs, John D, Strengholt, Sander, Parmentier, Julie M, Lippe, Ralph, Tanaka, Yoshiya

“…Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of…”
Get full text

Diagnosis and management of acute graft-versus-host disease by Dignan, Fiona L., Clark, Andrew, Amrolia, Persis, Cornish, Jacqueline, Jackson, Graham, Mahendra, Prem, Scarisbrick, Julia J., Taylor, Peter C., Hadzic, Nedim, Shaw, Bronwen E., Potter, Michael N.

“…Summary A joint working group established by the Haemato‐oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society…”
Get full text

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 by Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.

“…Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism…”
Get full text

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease by Taylor, Peter C, Askari, Ayman, Choy, Ernest, Ehrenstein, Michael R, Else, Sara, Nisar, Muhammad K

“…Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint pain and stiffness. Biologics represent some of the most effective…”
Get full text

Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus by Narayan, Nehal, Owen, David R, Mandhair, Harpreet, Smyth, Erica, Carlucci, Francesco, Saleem, Azeem, Gunn, Roger N, Rabiner, Eugenii A, Wells, Lisa, Dakin, Stephanie G, Sabokbar, Afsie, Taylor, Peter C

“…PET radioligands targeted to translocator protein (TSPO) offer a highly sensitive and specific means of imaging joint inflammation in rheumatoid arthritis…”
Get full text

The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis by Kragstrup, Tue W, Andersen, Thomas, Heftdal, Line D, Hvid, Malene, Gerwien, Jens, Sivakumar, Pallavur, Taylor, Peter C, Senolt, Ladislav, Deleuran, Bent

“…This review describes the IL-20 family of cytokines in rheumatoid arthritis (RA) and spondyloartrhitits (SpA) including psoriatic arthritis. The IL-20 receptor…”
Get full text

Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis by Whittle, Robert, Taylor, Peter C.

“…Extracorporeal photopheresis (ECP) is an important therapeutic option in steroid-refractory chronic graft-versus-host disease (cGVHD). Few biomarkers…”
Get full text

Diagnosis and management of chronic graft-versus-host disease by Dignan, Fiona L., Amrolia, Persis, Clark, Andrew, Cornish, Jacqueline, Jackson, Graham, Mahendra, Prem, Scarisbrick, Julia J., Taylor, Peter C., Shaw, Bronwen E., Potter, Michael N.

“…Summary A joint working group established by the Haemato‐oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society…”
Get full text